BioMarin Pharmaceutical Inc.
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Northen District of California on behalf of those who acquired BioMarin Pharmaceutical Inc. (“BioMarin” or the “Company”) (NASDAQ: BMRN) securities during the period from February 28, 2020 through August 18, 2020, inclusive (the "Class Period"). Investors have until November 24, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
According to the Complaint, the Company made false and misleading statements to the market. BioMarin’s Phase 3 trial of valoctocogene roxaparvovec differed from its Phase 1/2 trial, which lowered the reliability of the earlier study’s data on durability of effect. This put the Company at risk of the FDA not approving the BLA for valoctocogene roxaparvovec without the submission of additional supporting data. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about BioMarin, investors suffered damages.
If you acquired BioMarin securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at email@example.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.